Publications by authors named "Annabelle A Okada"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

2,792

Total Likes

19

Extended Reach

13,387

Social Features

16
E
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.
Masahito Ohji, Kanji Takahashi, Annabelle A Okada, Masato Kobayashi, Yoshimi Matsuda, Yasuhiro Terano,

Adv Ther· March 2020

Videos about Article: user

1 15 2

View All Article and Social Media Activity
I
International consensuses and guidelines on managing ocular Behçet's disease by the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), the Asia-Pacific Vitreo-Retina Society (APVRS), the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII) and the Academia Retina Internationalis (ARI).
Victor T T Chan, Andrew C Y Mak, Rupesh Agrawal, Jyotirmay Biswas, Bahram Bodaghi, Annabelle A Okada

Asia Pac J Ophthalmol (Phila)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complexities in the Terminology Used for Describing, Diagnosing, and Classifying Retinal Vasculitis: A Scoping Review from the International Uveitis Study Group (IUSG) Retinal Vasculitis Study (ReViSe)-Report 6.
Chen En Lucas Chua, William Rojas-Carabali, Carlos Cifuentes-González, Sapna Gangaputra, Marc D Smet, Annabelle A Okada

Ocul Immunol Inflamm· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of intraocular pressure elevation following intravitreal injection of 70 µl aflibercept 8 mg.
Xien Lu, Keiko Kataoka, Mariko Kumagai, Yuta Nochi, Akiko Yamamoto, Annabelle A Okada

Jpn J Ophthalmol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degeneration.
Keiko Kataoka, Koji Tanaka, Junichiro Honjyo, Yasunori Miyara, Nozomu Hashiya, Annabelle A Okada

Graefes Arch Clin Exp Ophthalmol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "International consensuses and guidelines on etiology, diagnosis, treatment, and future developments of neovascular age-related macular degeneration (nAMD) by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Ocular Imaging Society (APOIS) and the Academy of the Asia-Pacific Professors of Ophthalmology (AAPPO)" [Asia-Pac J Ophthalmol, Available online 29 August 2025, 100242 (2025) DOI:10.1016/j.apjo.2025.100242].
Timothy Y Y Lai, Keiko Kataoka, Yi-Ting Hsieh, Rajendra S Apte, Muna Bhende, Annabelle A Okada

Asia Pac J Ophthalmol (Phila)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demographic Features, Diagnoses and Real-World Clinical Management of Uveitis in Japan.
Isami Hayashi, Hiroshi Keino, Makiko Nakayama, Yoshimasa Ando, Takayo Watanabe, Annabelle A Okada

Ocul Immunol Inflamm· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors predictive of treatment outcomes in submacular hemorrhage secondary to age-related macular degeneration.
Yuto Watanabe, Takashi Koto, Aya Takahashi, Masaharu Mizuno, Tomoka Ishida, Annabelle A Okada

Jpn J Ophthalmol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Serum microRNAs During the Development of Experimental Autoimmune Uveoretinitis in Rats.
Shoko Saito, Hiroshi Keino, Ichiro Takasaki, Takayo Watanabe, Annabelle A Okada

Ocul Immunol Inflamm· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of central serous chorioretinopathy: new options for an old disease.
Yoon Jeon Kim, Sobha Sivaprasad, Tariq Aslam, Polona Jaki Mekjavić, Vilma Jūratė Balčiūnienė, Annabelle A Okada

Eye (Lond)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International consensuses and guidelines on etiology, diagnosis, treatment, and future developments of neovascular age-related macular degeneration (nAMD) by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Ocular Imaging Society (APOIS) and the Academy of the Asia-Pacific Professors of Ophthalmology (AAPPO).
Timothy Y Y Lai, Keiko Kataoka, Yi-Ting Hsieh, Rajendra S Apte, Muna Bhende, Annabelle A Okada

Asia Pac J Ophthalmol (Phila)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A post-hoc analysis of intravitreal aflibercept-treated nAMD patients from ARIES & ALTAIR: predicting treatment intervals and frequency for aflibercept treat-and-extend therapy regimen using machine learning.
Matthias Gutfleisch, Britta Heimes-Bussmann, Sökmen Aydin, Ratko Petrovic, Alexander Loktyushin, Annabelle A Okada

Graefes Arch Clin Exp Ophthalmol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration.
Kelvin Yi Chong Teo, Bora Eldem, Antonia Joussen, Adrian Koh, Jean-François Korobelnik, Annabelle A Okada

Eye (Lond)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FACTORS PREDICTIVE OF PERSISTENT SUBRETINAL FLUID IN ACUTE CENTRAL SEROUS CHORIORETINOPATHY.
Chika Hatakeyama, Keiko Kataoka, Yuji Yoshikawa, Makiko Nakayama, Akiko Yamamoto, Annabelle A Okada

Retina· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial.
Hideki Koizumi, Fumi Gomi, Akitaka Tsujikawa, Shigeru Honda, Ryusaburo Mori, Annabelle Ayame Okada

Graefes Arch Clin Exp Ophthalmol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan.
Ryo Mukai, Keiko Kataoka, Koji Tanaka, Yasunori Miyara, Ichiro Maruko, Annabelle A Okada

Sci Rep· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study.
Satoru Inoda, Hidenori Takahashi, Maiko Maruyama-Inoue, Shoko Ikeda, Tetsuju Sekiryu, Annabelle A Okada

Retina· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Keiko Kataoka, Kanako Itagaki, Nozumu Hashiya, Sorako Wakugawa, Koji Tanaka, Annabelle A Okada

Graefes Arch Clin Exp Ophthalmol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID Vaccine-Associated Uveitis.
Zohar Habot-Wilner, Piergiorgio Neri, Annabelle A Okada, Rupesh Agrawal, Ng Xin Le

Ocul Immunol Inflamm· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
Ryusaburo Mori, Shigeru Honda, Fumi Gomi, Akitaka Tsujikawa, Hideki Koizumi, Annabelle Ayame Okada

Jpn J Ophthalmol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
Ryusaburo Mori, Shigeru Honda, Fumi Gomi, Akitaka Tsujikawa, Hideki Koizumi, Annabelle Ayame Okada

Jpn J Ophthalmol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan.
Ryo Mukai, Keiko Kataoka, Koji Tanaka, Yasunori Miyara, Ichiro Maruko, Annabelle A Okada

Sci Rep· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 vaccination-related intraocular inflammation in Japanese patients.
Makiko Nakayama, Annabelle A Okada, Isami Hayashi, Hiroshi Keino

Graefes Arch Clin Exp Ophthalmol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study.
Masaru Takeuchi, Yoshihiko Usui, Kenichi Namba, Hiroshi Keino, Masaki Takeuchi, Annabelle A Okada

Front Med (Lausanne)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated Quantitative Analysis of Anterior Segment Inflammation Using Swept-Source Anterior Segment Optical Coherence Tomography: A Pilot Study.
Hiroshi Keino, Takuto Aman, Ryota Furuya, Makiko Nakayama, Annabelle A Okada

Diagnostics (Basel)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Analysis of Serum microRNA in Diagnosed Ocular Sarcoidosis versus Idiopathic Uveitis with Ocular Manifestations of Sarcoidosis.
Shoko Saito, Hiroshi Keino, Ichiro Takasaki, Shinya Abe, Hideo Kohno, Annabelle A Okada

Int J Mol Sci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis